Chimeric Therapeutics Limited (CHMMF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -3.05 Million AUD | 122.92% |
| 2023 | -2.36 Million AUD | 87.15% |
| 2022 | -18.38 Million AUD | 17.98% |
| 2021 | -22.41 Million AUD | -66193.13% |
| 2020 | 33.9 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -3.05 Million AUD | -29.22% |
| 2024 Q2 | -3.52 Million AUD | 0.0% |
| 2024 Q1 | -3.52 Million AUD | -49.21% |
| 2024 Q4 | -3.05 Million AUD | 0.0% |
| 2023 FY | -2.36 Million AUD | 87.15% |
| 2023 Q4 | -2.36 Million AUD | 56.0% |
| 2023 Q1 | -3.62 Million AUD | 80.27% |
| 2023 Q3 | -5.36 Million AUD | -48.08% |
| 2023 Q2 | -3.62 Million AUD | 0.0% |
| 2022 Q3 | -18.38 Million AUD | -36.86% |
| 2022 Q1 | -13.43 Million AUD | 40.07% |
| 2022 Q2 | -13.43 Million AUD | 0.0% |
| 2022 FY | -18.38 Million AUD | 17.98% |
| 2022 Q4 | -18.38 Million AUD | 0.0% |
| 2021 Q1 | 4.8 Million AUD | 0.0% |
| 2021 FY | -22.41 Million AUD | -66193.13% |
| 2021 Q3 | -22.41 Million AUD | -566.63% |
| 2021 Q4 | -22.41 Million AUD | 0.0% |
| 2021 Q2 | 4.8 Million AUD | 0.0% |
| 2020 FY | 33.9 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 364.231% |
| CSL Limited | 10.52 Billion USD | 100.029% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 119.368% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 174.138% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 859.738% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 107.134% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 51.574% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 429.276% |
| Mesoblast Limited | 55.85 Million USD | 105.466% |
| Marizyme, Inc. | 18.56 Million USD | 116.441% |
| Genus plc | 190.6 Million USD | 101.602% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 236.549% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 351.506% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 548.971% |
| ContraFect Corporation | -6.02 Million USD | 49.336% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 2367.546% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 139.802% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 155.49% |
| MultiCell Technologies, Inc. | 90.04 USD | 3390816.348% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -315.953% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 123.583% |
| EV Biologics, Inc. | 1.36 Million USD | 323.177% |
| Q BioMed Inc. | 4.06 Million USD | 175.197% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 109.992% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 402.962% |
| Biomind Labs Inc. | 711.4 Thousand USD | 529.153% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 123.839% |
| Skye Bioscience, Inc. | -5.72 Million USD | 46.639% |
| SQZ Biotechnologies Company | -36.23 Million USD | 91.575% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 2283.772% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 154.051% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 236.159% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 15467.197% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 590.549% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 102.78% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 454.901% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 238.648% |
| GB Sciences, Inc. | 1.74 Million USD | 274.725% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1561.154% |
| argenx SE | -2.02 Billion USD | 99.85% |
| HST Global, Inc. | 96.79 Thousand USD | 3254.155% |
| Halberd Corporation | 144.72 Thousand USD | 2209.577% |
| Enzolytics Inc. | 981.65 Thousand USD | 411.005% |
| Resverlogix Corp. | 6.45 Million USD | 147.326% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -353.581% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 107.029% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 105.042% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 93.506% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 252.696% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 143.177% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 948.74% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 212.714% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 65.463% |
| AVAX Technologies, Inc. | -5.9 Million USD | 48.282% |
| ONE Bio Corp. | 9.04 Million USD | 133.772% |
| Zenith Capital Corp. | 10.06 Thousand USD | 30435.86% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.712% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1623.21% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 227.953% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1955.826% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -16566.672% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1580.48% |
| Agentix Corp. | 37.63 Thousand USD | 8212.995% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -1106.233% |
| Helix BioMedix, Inc. | -2.57 Million USD | -18.792% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 115.057% |
| BioStem Technologies, Inc. | 4.47 Million USD | 168.269% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1616.989% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -232953.511% |
| LadRx Corporation | -2.03 Million USD | -49.916% |
| Cell Source, Inc. | 9.23 Million USD | 133.07% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -14859.825% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 580.661% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 580.661% |
| NovAccess Global Inc. | 2.17 Million USD | 240.145% |
| Affymax, Inc. | -5.59 Million USD | 45.453% |
| Itoco Inc. | 228.3 Thousand USD | 1437.247% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 2345.035% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 161.59% |
| CytoDyn Inc. | 20.26 Million USD | 115.068% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -471770.325% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -32840.106% |
| Qrons Inc. | 351.42 Thousand USD | 968.744% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 139.618% |
| SYBLEU INC | 473.71 Thousand USD | 744.482% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -1123.059% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1100.984% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 168.499% |
| Mobile Lads Corp. | 484.23 Thousand USD | 730.483% |
| International Stem Cell Corporation | 2.59 Million USD | 217.876% |
| Bioxytran, Inc. | 1.89 Million USD | 260.776% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 4991.611% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 239.988% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 188.905% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 135.695% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 495.156% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -144.24% |
| Neutra Corp. | 52.18 Thousand USD | 5950.118% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -22.66% |
| PureTech Health plc | -167.19 Million USD | 98.174% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -1146.591% |
| IXICO plc | -4.44 Million USD | 31.31% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 123.096% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 105.566% |
| CSL Limited | 10.52 Billion USD | 100.029% |
| Cellectis S.A. | -43.81 Million USD | 93.033% |